Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 600 participants.

Also called NCT05465031

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 600 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05465031
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Poland (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05465031. Randomized; triple masking; primary purpose prevention. Start 2024-04-17 (actual); primary completion 2027-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)
Condition
Breast Cancer
Condition
Neoplasm, Breast
Condition
Breast Diseases
Condition
Antihypertensive Agents
Condition
Sacubitril/Valsartan
Condition
Angiotensin II Type 1 Receptor Blockers
Condition
Molecular Mechanisms of Pharmacological Action
Condition
Heart Failure
Condition
Cardiac Toxicity
Condition
Cancer, Therapy-Related
Condition
Cancer Therapy-Related Cardiac Dysfunction
Condition
Cardiotoxicity
Intervention (Drug)
Sacubitril-valsartan
Intervention (Drug)
Placebo
Lead sponsor
Silesian Centre for Heart Diseases (class: other)
Collaborator
Medical Research Agency, Poland (class: other government)

Record details

Record id
cardio:ct-nct05465031
Content hash
e30d0411ecdc5b7932aa419a62c28d8c84e1b98487feaa9948ffa350a257d84e